PDS Biotechnology to Report 2025 Financial Results and Provide Clinical Update
PDS Biotechnology will report 2025 financial results and provide clinical updates on March 30, 2026. The company faces critical regulatory decisions for its Phase 3 VERSATILE-003 trial in HPV16-positive head and neck cancer and is expanding its immunotherapy platform to prostate cancer and other solid tumors.
PDS Biotechnology Corporation will host a conference call and webcast to report financial results for the quarter and year ended December 31, 2025, and will provide a clinical programs and corporate update on Monday, March 30, 2026 at 8:00 am Eastern Time. The company is navigating a pivotal period in its development pipeline, with key strategic decisions on the horizon that could accelerate its path to market.
The company has scheduled a comprehensive strategy update and the release of its full-year 2025 financial results for March 26. This presentation is expected to provide crucial details on liquidity reserves and the funding strategy for its costly Phase 3 trial initiatives.
At the core of PDS Biotechnology's near-term prospects is the VERSATILE-003 trial, a Phase 3 study evaluating a combination therapy for HPV16-positive head and neck cancer. Patient recruitment for this study commenced in early 2025. A significant potential catalyst involves a pending regulatory submission concerning the trial's design, with the company seeking to establish progression-free survival as the primary endpoint. This modification, if approved, would allow for a substantially earlier assessment of the therapy's efficacy compared to the original protocol.
Beyond its lead program, the company is building evidence for its platform's application across various solid tumors. The development of PDS01ADC for prostate cancer is a key component of this strategy, intended to showcase the adaptability of the underlying technology. Following the release of initial early-phase study data in late January 2026, the market is now monitoring the durability of the clinical responses observed.
PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers. The company has initiated a pivotal clinical trial to advance its lead program in advanced HPV16-positive head and neck squamous cell cancers. PDS Biotech's lead investigational targeted immunotherapy PDS0101 is being developed in combination with a standard-of-care immune checkpoint inhibitor, and also in a triple combination including PDS01ADC, an IL-12 fused antibody drug conjugate (ADC), and a standard-of-care immune checkpoint inhibitor. PDS01ADC is being evaluated in multiple phase 2 trials in various cancer indications in combination with standard of care.